Stay updated on SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.

Latest updates to the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedAdded a new revision label (v3.4.2) to the record history and removed older notices (v3.4.1 and the funding-status notice). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check21 days agoChange DetectedA government funding lapse notice was added and the record history shows a new Revision: v3.4.1 (replacing v3.4.0); these are administrative updates and do not affect core study data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check28 days agoChange DetectedAdded a glossary toggle and color-coded highlights for added/deleted items. Updated revision notes to v3.4.0 (replacing v3.3.4).SummaryDifference1%

- Check42 days agoChange DetectedRevision history updated to include v3.3.4 and remove v3.3.3 for the study NCT04293276.SummaryDifference0.1%

- Check63 days agoChange DetectedThe page history now shows a new revision (v3.3.3); the HHS Vulnerability Disclosure link and the older revision (v3.3.2) were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check92 days agoChange DetectedThe Record History now shows a new revision: v3.3.2, replacing the previous v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SHR6390 & Pyrotinib in HER2+ Breast Cancer Clinical Trial page.